Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder

IF 3.9 2区医学 Q1 PSYCHIATRY

Drug and alcohol dependence Pub Date : 2025-03-26 DOI:10.1016/j.drugalcdep.2025.112663

Jacob D. Baylis , Terri L. Jorgenson , Haley E. Pals , Catherine S. Hwang , Michelle D. Colvard , Veldana Alliu , Tera Moore , Lewei A. Lin , Jessica Wyse , Eric J. Hawkins , Hildi J. Hagedorn , Adam J. Gordon

{"title":"Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder","authors":"Jacob D. Baylis , Terri L. Jorgenson , Haley E. Pals , Catherine S. Hwang , Michelle D. Colvard , Veldana Alliu , Tera Moore , Lewei A. Lin , Jessica Wyse , Eric J. Hawkins , Hildi J. Hagedorn , Adam J. Gordon","doi":"10.1016/j.drugalcdep.2025.112663","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Clinical Pharmacist Practitioners (CPPs) have a long history of collaborating with other prescribers for the provision of buprenorphine medication treatment for opioid use disorder (B-MOUD). In January 2023, with the removal of the DATA 2000 X-waiver process, CPPs were allowed to prescribe B-MOUD in states that allow CPP prescriptive authority of controlled substances. We sought to examine CPP prescribing patterns of B-MOUD in a large heath care system in 2023.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of patients with opioid use disorder (OUD) who received B-MOUD care in 2023 within the Veterans Health Administration (VHA). B-MOUD was defined as a formulation of buprenorphine indicated for OUD. We characterized Veterans who were prescribed B-MOUD by CPPs and examined the characteristics of these prescriptions and the episodes of care (EOC).</div></div><div><h3>Results</h3><div>In 2023, 22,863 Veterans received B-MOUD; 1090 (4.8 %) from a CPP. Veterans prescribed B-MOUD by CPPs were primarily 36–50 years old (n = 419, 38.4 %), male (n = 987, 90.6 %), white (n = 987, 90.6 %), non-Hispanic/Latino (n = 1043, 95.7 %), and in urban areas (n = 648, 59.4 %). 110 CPPs prescribed B-MOUD in 36 states representing 1.9 % of all B-MOUD prescribers in 2023. CPPs prescribed 5258 B-MOUD prescriptions, conducted 339 (2.7 %) initiations, were involved in 1162 (4.2 %) of all EOC throughout the year, and were the sole prescriber for 16.6 % of EOC. CPP-involved EOC had 86.9 % (n = 867) 90-day retention.</div></div><div><h3>Conclusion</h3><div>When they were able to, VHA CPPs were early adopters in prescribing B-MOUD. B-MOUD prescribing by CPPs is an emerging opportunity to further expand access to B-MOUD.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"271 ","pages":"Article 112663"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871625001164","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Clinical Pharmacist Practitioners (CPPs) have a long history of collaborating with other prescribers for the provision of buprenorphine medication treatment for opioid use disorder (B-MOUD). In January 2023, with the removal of the DATA 2000 X-waiver process, CPPs were allowed to prescribe B-MOUD in states that allow CPP prescriptive authority of controlled substances. We sought to examine CPP prescribing patterns of B-MOUD in a large heath care system in 2023.

Methods

We conducted a retrospective cohort study of patients with opioid use disorder (OUD) who received B-MOUD care in 2023 within the Veterans Health Administration (VHA). B-MOUD was defined as a formulation of buprenorphine indicated for OUD. We characterized Veterans who were prescribed B-MOUD by CPPs and examined the characteristics of these prescriptions and the episodes of care (EOC).

Results

In 2023, 22,863 Veterans received B-MOUD; 1090 (4.8 %) from a CPP. Veterans prescribed B-MOUD by CPPs were primarily 36–50 years old (n = 419, 38.4 %), male (n = 987, 90.6 %), white (n = 987, 90.6 %), non-Hispanic/Latino (n = 1043, 95.7 %), and in urban areas (n = 648, 59.4 %). 110 CPPs prescribed B-MOUD in 36 states representing 1.9 % of all B-MOUD prescribers in 2023. CPPs prescribed 5258 B-MOUD prescriptions, conducted 339 (2.7 %) initiations, were involved in 1162 (4.2 %) of all EOC throughout the year, and were the sole prescriber for 16.6 % of EOC. CPP-involved EOC had 86.9 % (n = 867) 90-day retention.

Conclusion

When they were able to, VHA CPPs were early adopters in prescribing B-MOUD. B-MOUD prescribing by CPPs is an emerging opportunity to further expand access to B-MOUD.

查看原文本刊更多论文

临床药师从业人员处方丁丙诺啡阿片类药物使用障碍

临床药师从业人员（CPPs）与其他开处方者合作提供丁丙诺啡药物治疗阿片类药物使用障碍（b - mod）的历史悠久。2023年1月，随着DATA 2000 x豁免程序的取消，CPP被允许在允许CPP管制物质的州开b - mod处方。我们试图在2023年检查大型医疗保健系统中b - mod的CPP处方模式。方法对2023年在退伍军人健康管理局（VHA）接受b - mode治疗的阿片类药物使用障碍（OUD）患者进行回顾性队列研究。b - mod定义为用于OUD的丁丙诺啡制剂。我们对cps开具b - mod的退伍军人进行了研究，并检查了这些处方的特征和护理发作（EOC）。结果2023年，22,863名退伍军人接受b - mode治疗；1090（4.8%）来自CPP。CPPs开具b - mod的退伍军人主要为36-50岁（n = 419, 38.4%）、男性（n = 987, 90.6%）、白人（n = 987, 90.6%）、非西班牙裔/拉丁裔（n = 1043, 95.7%）和城市地区（n = 648, 59.4%）。36个州的110个cpp开出b - mod处方，占2023年所有b - mod处方者的1.9%。cps开了5258张b - mod处方，进行了339次（2.7%）的启动，涉及全年所有EOC的1162次（4.2%），并且是16.6% EOC的唯一开处方者。cpp相关的EOC 90天保留率为86.9% （n = 867）。结论在条件允许的情况下，VHA cps是较早使用b - mod的患者。cps开具b - mod处方是进一步扩大b - mod可及性的一个新机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug and alcohol dependence 医学-精神病学

CiteScore

7.40

自引率

7.10%

发文量

409

审稿时长

41 days

期刊介绍： Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.